Chronic Lower Back Pain Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Chronic Lower Back Pain Treatment Market
The chronic lower back pain treatment market size was reached at a value of USD 2.21 billion in 2022, and the market is now projected to rise from USD 2.40 billion in 2023 to USD 4.50 billion by 2030, exhibiting a CAGR of 9.5% during the forecast period of 2023-2030.
The covid outbreak had a negative effect on market growth due to more emphasis on covid patients, limited availability of resources such as staff shortage and government imposed social distancing measures during current situation. Due to the reduction in number of chronic lower back pain cases during COVID-19 pandemic the market led to reduction in growth.
Increasing prevalence of chronic lower backpain due to sedentary lifestyle, psychological distress, and increasing obesity leading the market expansion. In addition, increasing incidence of this ailment in the general population driving the chronic lower back pain treatment market growth. Manufacturers are focusing on developing new pharmaceuticals to address increased need for effective therapeutic measures augmenting chronic lower back pain treatment growth. Market players are releasing medications at lower prices and stressing their global availability which is impacting patient preference for drug therapy fueling market expansion.
Additionally, due to implementation of advanced technology for drug delivery offers remarkable opportunities for market growth. Use of novel approach in drug delivery to treat lower back pain is fostering market growth.Scientists are putting their emphasis on creative treatments to alleviate chronic lower back pain, including for people who have undergone surgery augmenting chronic lower back pain treatment growth.
Comprehensive Analysis of Chronic Lower Back Pain Treatment Market
The chronic lower back pain treatment market is rising with an exponential rate due to its market segmentation. These segmentations are methodically segregated by drug class, by route of administration and by distribution channel. The types of Drug Class segment include Antidepressants, Analgesic, Non-steroidal Anti-Inflammatory Drugs, Opioids, and Others, and By Route of Administration segment include Topical, Oral, and Others, while By Distribution Channel segment include Retail & Online Pharmacies and Hospital Pharmacies.
In the chronic lower back pain treatment market, North America region lead the healthcare devices market by benefitting a market size of USD 1.04 billion in 2022 owing to rising prevalence of backpain due to sedentary lifestyle and implementation of advanced technology for drug delivery.
The prominent players in the market play a crucial role in the chronic lower back pain treatment industry assuring industrial prospectus growth and setting market standards. These prominent market players include, Endo International plc. (Ireland) Lilly (U.S.), Johnson & Johnson Services, Inc. (U.S.), Merck & Co, Inc. (U.S.), Sanofi (France), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Dr. Reddy's Laboratories Ltd. (India), Bayer AG (Germany) and GSK plc (U.K.), these market key players provide a level-playing competitive environment.
In July 2023, Sanofi sold Neuraxpharm 17 medicines, including Tramadol, a painkiller.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2019-2030
Base Year 2022
Estimated Year 2023
Forecast Period 2023-2030
Historical Period 2019-2021
Growth Rate CAGR of 9.5% from 2023 to 2030
Unit Value (USD billion)
Segmentation By Drug Class, Route of Administration, Distribution Channel, and Region
By Drug Class Non-steroidal Anti-Inflammatory Drugs
Antidepressants
Analgesic
Opioids
Others
By Route of Administration Oral
Topical
Others
By Distribution Channel Hospital Pharmacies
Retail & Online Pharmacies
By Region North America (By Drug Class, By Route of Administration, By Distribution Channel, By Country/Sub-Region)
- U.S.
- Canada
Europe (By Drug Class, By Route of Administration, By Distribution Channel, By Country/Sub-Region)
- U.K.
- Germany
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
Asia Pacific (By Drug Class, By Route of Administration, By Distribution Channel, By Country/Sub-Region)
- China
- India
- Japan
- Australia
- Southeast Asia
- Rest of Asia Pacific
Latin America (By Drug Class, By Route of Administration, By Distribution Channel, By Country/Sub-Region)
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa (By Drug Class, By Route of Administration, By Distribution Channel, By Country/Sub-Region)
- GCC
- South Africa
- Rest of Middle East & Africa
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 4. Key Insights
- 4.1. Prevalence of Chronic Lower Back Pain, By Key Countries, 2022
- 4.2. Pipeline Analysis, Key Players
- 4.3. Key Industry Developments, Key Players
- 4.4. Impact of COVID-19 on the Market
- 5. Global Chronic Lower Back Pain Treatment Market Analysis, Insights and Forecast, 2019-2030
- 5.1. Market Analysis, Insights and Forecast – By Drug Class
- 5.1.1. Non-steroidal Anti-Inflammatory Drugs
- 5.1.2. Antidepressants
- 5.1.3. Analgesic
- 5.1.4. Opioids
- 5.1.5. Others
- 5.2. Market Analysis, Insights and Forecast – By Route of Administration
- 5.2.1. Oral
- 5.2.2. Topical
- 5.2.3. Others
- 5.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.3.1. Hospital Pharmacies
- 5.3.2. Retail & Online Pharmacies
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa
- 6. North America Chronic Lower Back Pain Treatment Market Analysis, Insights and Forecast, 2019-2029
- 6.1. Market Analysis, Insights and Forecast – By Drug Class
- 6.1.1. Non-steroidal Anti-Inflammatory Drugs
- 6.1.2. Antidepressants
- 6.1.3. Analgesic
- 6.1.4. Opioids
- 6.1.5. Others
- 6.2. Market Analysis, Insights and Forecast – By Route of Administration
- 6.2.1. Oral
- 6.2.2. Topical
- 6.2.3. Others
- 6.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 6.3.1. Hospital Pharmacies
- 6.3.2. Retail & Online Pharmacies
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.2. Canada
- 7. Europe Chronic Lower Back Pain Treatment Market Analysis, Insights and Forecast, 2019-2030
- 7.1. Market Analysis, Insights and Forecast – By Drug Class
- 7.1.1. Non-steroidal Anti-Inflammatory Drugs
- 7.1.2. Antidepressants
- 7.1.3. Analgesic
- 7.1.4. Opioids
- 7.1.5. Others
- 7.2. Market Analysis, Insights and Forecast – By Route of Administration
- 7.2.1. Oral
- 7.2.2. Topical
- 7.2.3. Others
- 7.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 7.3.1. Hospital Pharmacies
- 7.3.2. Retail & Online Pharmacies
- 7.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region
- 7.4.1. U.K.
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Scandinavia
- 7.4.7. Rest of Europe
- 8. Asia Pacific Chronic Lower Back Pain Treatment Market Analysis, Insights and Forecast, 2019-2030
- 8.1. Market Analysis, Insights and Forecast – By Drug Class
- 8.1.1. Non-steroidal Anti-Inflammatory Drugs
- 8.1.2. Antidepressants
- 8.1.3. Analgesic
- 8.1.4. Opioids
- 8.1.5. Others
- 8.2. Market Analysis, Insights and Forecast – By Route of Administration
- 8.2.1. Oral
- 8.2.2. Topical
- 8.2.3. Others
- 8.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 8.3.1. Hospital Pharmacies
- 8.3.2. Retail & Online Pharmacies
- 8.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region
- 8.4.1. China
- 8.4.2. India
- 8.4.3. Japan
- 8.4.4. Australia
- 8.4.5. South East Asia
- 8.4.6. Rest of Asia Pacific
- 9. Latin America Chronic Lower Back Pain Treatment Market Analysis, Insights and Forecast, 2019-2030
- 9.1. Market Analysis, Insights and Forecast – By Drug Class
- 9.1.1. Non-steroidal Anti-Inflammatory Drugs
- 9.1.2. Antidepressants
- 9.1.3. Analgesic
- 9.1.4. Opioids
- 9.1.5. Others
- 9.2. Market Analysis, Insights and Forecast – By Route of Administration
- 9.2.1. Oral
- 9.2.2. Topical
- 9.2.3. Others
- 9.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 9.3.1. Hospital Pharmacies
- 9.3.2. Retail & Online Pharmacies
- 9.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
- 10. Middle East & Africa Chronic Lower Back Pain Treatment Market Analysis, Insights and Forecast, 2019-2030
- 10.1. Market Analysis, Insights and Forecast – By Drug Class
- 10.1.1. Non-steroidal Anti-Inflammatory Drugs
- 10.1.2. Antidepressants
- 10.1.3. Analgesic
- 10.1.4. Opioids
- 10.1.5. Others
- 10.2. Market Analysis, Insights and Forecast – By Route of Administration
- 10.2.1. Oral
- 10.2.2. Topical
- 10.2.3. Others
- 10.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 10.3.1. Hospital Pharmacies
- 10.3.2. Retail & Online Pharmacies
- 10.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region
- 10.4.1. GCC
- 10.4.2. South Africa
- 10.4.3. Rest of Middle East & Africa
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis (2022)
- 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
- 11.2.1. Pfizer Inc.
- 11.2.1.1. Overview,
- 11.2.1.2. Products,
- 11.2.1.3. SWOT Analysis,
- 11.2.1.4. Recent Developments,
- 11.2.1.5. Strategies,
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Lilly
- 11.2.2.1. Overview,
- 11.2.2.2. Products,
- 11.2.2.3. SWOT Analysis,
- 11.2.2.4. Recent Developments,
- 11.2.2.5. Strategies,
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. GSK plc
- 11.2.3.1. Overview,
- 11.2.3.2. Products,
- 11.2.3.3. SWOT Analysis,
- 11.2.3.4. Recent Developments,
- 11.2.3.5. Strategies,
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Johnson & Johnson Services, Inc.
- 11.2.4.1. Overview,
- 11.2.4.2. Products,
- 11.2.4.3. SWOT Analysis,
- 11.2.4.4. Recent Developments,
- 11.2.4.5. Strategies,
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Merck & Co, Inc.
- 11.2.5.1. Overview,
- 11.2.5.2. Products,
- 11.2.5.3. SWOT Analysis,
- 11.2.5.4. Recent Developments,
- 11.2.5.5. Strategies,
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Sanofi
- 11.2.6.1. Overview,
- 11.2.6.2. Products,
- 11.2.6.3. SWOT Analysis,
- 11.2.6.4. Recent Developments,
- 11.2.6.5. Strategies,
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. Novartis AG
- 11.2.7.1. Overview,
- 11.2.7.2. Products,
- 11.2.7.3. SWOT Analysis,
- 11.2.7.4. Recent Developments,
- 11.2.7.5. Strategies,
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Dr. Reddy's Laboratories
- 11.2.8.1. Overview,
- 11.2.8.2. Products,
- 11.2.8.3. SWOT Analysis,
- 11.2.8.4. Recent Developments,
- 11.2.8.5. Strategies,
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Bayer AG
- 11.2.9.1. Overview,
- 11.2.9.2. Products,
- 11.2.9.3. SWOT Analysis,
- 11.2.9.4. Recent Developments,
- 11.2.9.5. Strategies,
- 11.2.9.6. Financials (Based on Availability)
- 11.2.10. Endo International plc.
- 11.2.10.1. Overview,
- 11.2.10.2. Products,
- 11.2.10.3. SWOT Analysis,
- 11.2.10.4. Recent Developments,
- 11.2.10.5. Strategies,
- 11.2.10.6. Financials (Based on Availability)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook